HERON THERAPEUTICS, INC. /DE/ 8-K

What Happened

• Heron Therapeutics, Inc. (HRTX) filed a Form 8-K on February 26, 2026 to announce its financial results for the three- and twelve-month periods ended December 31, 2025. The company issued an earnings press release on that date; the press release is furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: February 26, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Period covered: three- and twelve-months ended December 31, 2025 (Q4 2025 and full-year 2025).
• Disclosure format: Earnings press release furnished as Exhibit 99.1; interactive Inline XBRL cover page included (Exhibit 104).
• The 8-K furnishes the press release; it does not include additional financial tables or other exhibits beyond the press release and XBRL cover page in this filing.

Why It Matters

• Earnings releases provide the updated revenue, profit/loss, and operational metrics that investors use to evaluate company performance and adjust valuation.
• Because this 8-K furnishes Heron’s Q4 and full-year 2025 results, investors should review the press release (Exhibit 99.1) and any subsequent filings (e.g., quarterly or annual reports) for specific figures, trends, and management commentary that can influence trading and investment decisions.